- Developed the material promoting stem cell for chondrogenic cell differentiation - Submitted the IND (Prostemics=January. 05. 2017) Prostemics, Korean bio company, announced that they registered technological patent for treatment of Chondropathy on January 5, 2017. The patent title is ‘Pharmaceutical composition for prevention and treatment of Chodropathy’. Prostemics said “We discovered and proved that the animal originated material is promoting stem cell for chondrogenic cell differentiation” and “Prostemics is going to finalize technology for prevention and treatment of Chodropathy”. Prostemics said that they submitted IND for regenerative medicine for Arthritis based on this patent to the Ministry of Food and Drug Safety (MFDS, formerly known as the Korea Food & Drug Administration or KFDA) at the end of last year.